UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy.

Douglas, Kenneth W, Gilleece, Maria, Hayden, Patrick, Hunter, Hannah, Johnson, Peter R E, Kallmeyer, Charlotte, Malladi, Ram K, Paneesha, Shankara, Pawson, Rachel, Quinn, Michael, Raj, Kavita, Richardson, Deborah, Robinson, Stephen, Russell, Nigel, Snowden, John, Sureda, Anna, Tholouli, Eleni, Thomson, Kirsty, Watts, Mike and Wilson, Keith M (2017) UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy. Journal of clinical apheresis. ISSN 1098-1101. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs

Full text not available from this repository.
Official URL: http://onlinelibrary.wiley.com/journal/10.1002/(IS...

Abstract

Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail. Pre-emptive use has the advantage that it avoids the need to re-schedule the transplant procedure, with its attendant inconvenience, quality-of-life issues for the patient and cost of additional admissions to the transplant unit. UK experience from 2 major centers suggests that pre-emptive plerixafor is associated with an incremental drug cost of less than £2000 when averaged over all patients undergoing peripheral blood stem cell (PBSC) transplant. A CD34+ cell count of <15 µl(-1) at the time of recovery after chemomobilization or after four days of G-CSF treatment, or an apheresis yield of <1 × 10(6) CD34+ cells/kg on the first day of apheresis, could be used to predict the need for pre-emptive plerixafor.

Item Type: Article
Additional Information: This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Subjects: QZ Pathology. Oncology
WH Haemic and lymphatic systems. Haematology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Mrs Caroline Tranter
Date Deposited: 23 Jun 2017 15:25
Last Modified: 23 Jun 2017 15:25
URI: http://www.repository.uhblibrary.co.uk/id/eprint/1424

Actions (login required)

View Item View Item